| scholarly article | Q13442814 |
| P2093 | author name string | C A Kim | |
| H Lim | |||
| J Park | |||
| S Ahmed | |||
| J Davies | |||
| K Mulder | |||
| C Doll | |||
| A Zaidi | |||
| V Gordon | |||
| T Hamilton | |||
| M Ferguson | |||
| P Hebbard | |||
| D Renouf | |||
| B Brunet | |||
| D M Le | |||
| J M Loree | |||
| J P McGhie | |||
| R Lee-Ying | |||
| R P W Wong | |||
| N Ginther | |||
| R Helewa | |||
| T Asif | |||
| P2860 | cites work | Follow-up strategies for patients treated for non-metastatic colorectal cancer | Q24243018 |
| Impact on survival of intensive follow up after curative resection for colorectal cancer: systematic review and meta-analysis of randomised trials | Q24514818 | ||
| Follow-up of patients with curatively resected colorectal cancer: a practice guideline | Q24641986 | ||
| Surgical resection of hepatic metastases from colorectal cancer: a systematic review of published studies | Q24651894 | ||
| Chemotherapy for intraperitoneal use: a review of hyperthermic intraperitoneal chemotherapy and early post-operative intraperitoneal chemotherapy | Q26768402 | ||
| Meta-analysis of BRAF mutation as a predictive biomarker of benefit from anti-EGFR monoclonal antibody therapy for RAS wild-type metastatic colorectal cancer | Q27027648 | ||
| K-ras mutations and benefit from cetuximab in advanced colorectal cancer. | Q27851454 | ||
| Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial | Q27853380 | ||
| PD-1 Blockade in Tumors with Mismatch-Repair Deficiency | Q28262647 | ||
| Panitumumab-FOLFOX4 treatment and RAS mutations in colorectal cancer | Q28298328 | ||
| Follow-up strategies for patients treated for non-metastatic colorectal cancer. | Q30240736 | ||
| Adjuvant chemotherapy after preoperative (chemo)radiotherapy and surgery for patients with rectal cancer: a systematic review and meta-analysis of individual patient data | Q30884451 | ||
| Association Between Intensity of Posttreatment Surveillance Testing and Detection of Recurrence in Patients With Colorectal Cancer | Q56872721 | ||
| Preoperative assessment of prognostic factors in rectal cancer using high-resolution magnetic resonance imaging | Q57088951 | ||
| BRAF-V600E is not involved in the colorectal tumorigenesis of HNPCC in patients with functional MLH1 and MSH2 genes | Q57200503 | ||
| Effect of More vs Less Frequent Follow-up Testing on Overall and Colorectal Cancer–Specific Mortality in Patients With Stage II or III Colorectal Cancer | Q57299783 | ||
| FOLFOXIRI plus bevacizumab as first-line treatment in BRAF mutant metastatic colorectal cancer | Q59218920 | ||
| T3N0 rectal cancer: results following sharp mesorectal excision and no adjuvant therapy | Q73164021 | ||
| Rectal carcinoma: thin-section MR imaging for staging in 28 patients | Q77216061 | ||
| Randomized Trial of Cytoreduction and Hyperthermic Intraperitoneal Chemotherapy Versus Systemic Chemotherapy and Palliative Surgery in Patients With Peritoneal Carcinomatosis of Colorectal Cancer | Q79150738 | ||
| Effect of Primary Tumor Location on Second- or Later-line Treatment Outcomes in Patients With RAS Wild-type Metastatic Colorectal Cancer and All Treatment Lines in Patients With RAS Mutations in Four Randomized Panitumumab Studies | Q88298705 | ||
| Efficacy and Tolerability of First-Line Cetuximab Plus Leucovorin, Fluorouracil, and Oxaliplatin (FOLFOX-4) Versus FOLFOX-4 in Patients With RAS Wild-Type Metastatic Colorectal Cancer: The Open-Label, Randomized, Phase III TAILOR Trial | Q91356981 | ||
| Impact of T and N substage on survival and disease relapse in adjuvant rectal cancer: a pooled analysis. | Q40632454 | ||
| Location of colon cancer (right-sided versus left-sided) as a prognostic factor and a predictor of benefit from cetuximab in NCIC CO.17. | Q40933980 | ||
| Recent developments in the treatment of metastatic colorectal cancer. | Q41105389 | ||
| A randomized trial of intensive versus minimal surveillance of patients with resected Dukes B2-C colorectal carcinoma | Q41116967 | ||
| Trends in cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for the treatment of synchronous peritoneal carcinomatosis of colorectal origin in the Netherlands | Q41437643 | ||
| Patterns of recurrence of rectal cancer after potentially curative surgery | Q41441659 | ||
| Oxaliplatin added to fluorouracil-based preoperative chemoradiotherapy and postoperative chemotherapy of locally advanced rectal cancer (the German CAO/ARO/AIO-04 study): final results of the multicentre, open-label, randomised, phase 3 trial | Q41572461 | ||
| Role of Deficient DNA Mismatch Repair Status in Patients With Stage III Colon Cancer Treated With FOLFOX Adjuvant Chemotherapy: A Pooled Analysis From 2 Randomized Clinical Trials | Q42695264 | ||
| Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. | Q43932503 | ||
| Preoperative magnetic resonance imaging assessment of circumferential resection margin predicts disease-free survival and local recurrence: 5-year follow-up results of the MERCURY study. | Q46031466 | ||
| Comparison of transanal endoscopic microsurgery with or without neoadjuvant therapy and standard total mesorectal excision in the treatment of clinical T2 low rectal cancer: a meta-analysis | Q49319988 | ||
| Classifying colorectal cancer by tumor location rather than sidedness highlights a continuum in mutation profiles and Consensus Molecular Subtypes | Q49586760 | ||
| Durable Clinical Benefit With Nivolumab Plus Ipilimumab in DNA Mismatch Repair-Deficient/Microsatellite Instability-High Metastatic Colorectal Cancer | Q49887005 | ||
| Relevance, pathogenesis, and testing algorithm for mismatch repair-defective colorectal carcinomas: a report of the association for molecular pathology. | Q51442155 | ||
| Adoption of Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer. | Q52642667 | ||
| Modified FOLFOX6 With or Without Radiation Versus Fluorouracil and Leucovorin With Radiation in Neoadjuvant Treatment of Locally Advanced Rectal Cancer: Initial Results of the Chinese FOWARC Multicenter, Open-Label, Randomized Three-Arm Phase III Tr | Q53058608 | ||
| Cytoreductive surgery combined with perioperative intraperitoneal chemotherapy for the management of peritoneal carcinomatosis from colorectal cancer: a multi-institutional study. | Q53286355 | ||
| Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer: a multifactorial model of 929 patients. | Q53444980 | ||
| End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group | Q31129788 | ||
| Defective mismatch repair as a predictive marker for lack of efficacy of fluorouracil-based adjuvant therapy in colon cancer | Q33586020 | ||
| Capecitabine and oxaliplatin in the preoperative multimodality treatment of rectal cancer: surgical end points from National Surgical Adjuvant Breast and Bowel Project trial R-04 | Q33729092 | ||
| Initial therapy with FOLFOXIRI and bevacizumab for metastatic colorectal cancer. | Q34444495 | ||
| Impact of T and N stage and treatment on survival and relapse in adjuvant rectal cancer: a pooled analysis. | Q34546881 | ||
| Preoperative versus postoperative chemoradiotherapy for rectal cancer | Q34552041 | ||
| Clinical outcome of the ACCORD 12/0405 PRODIGE 2 randomized trial in rectal cancer | Q34644719 | ||
| BRAFV600E immunohistochemistry facilitates universal screening of colorectal cancers for Lynch syndrome | Q34782265 | ||
| Comparison of Transanal Endoscopic Microsurgery and Total Mesorectal Excision in the Treatment of T1 Rectal Cancer: A Meta-Analysis | Q35822871 | ||
| Transanal endoscopic microsurgery for rectal cancer: T1 and beyond? An evidence-based review. | Q35931639 | ||
| Prognostic Survival Associated With Left-Sided vs Right-Sided Colon Cancer: A Systematic Review and Meta-analysis | Q36175906 | ||
| The degree of extramural spread of T3 rectal cancer: an appeal to the American Joint Committee on Cancer | Q36203331 | ||
| The consensus molecular subtypes of colorectal cancer | Q36258187 | ||
| Molecular Biomarkers for the Evaluation of Colorectal Cancer: Guideline From the American Society for Clinical Pathology, College of American Pathologists, Association for Molecular Pathology, and the American Society of Clinical Oncology. | Q36271327 | ||
| Neoadjuvant chemotherapy prior to preoperative chemoradiation or radiation in rectal cancer: should we be more cautious? | Q36390229 | ||
| Survival after hepatic resection for colorectal metastases: a 10-year experience | Q36416294 | ||
| An analysis of the treatment effect of panitumumab on overall survival from a phase 3, randomized, controlled, multicenter trial (20020408) in patients with chemotherapy refractory metastatic colorectal cancer. | Q36892835 | ||
| Follow-up after curative resection of colorectal cancer: a meta-analysis | Q36943822 | ||
| Extended RAS mutations and anti-EGFR monoclonal antibody survival benefit in metastatic colorectal cancer: a meta-analysis of randomized, controlled trials | Q38239192 | ||
| Intensive follow-up strategies improve outcomes in nonmetastatic colorectal cancer patients after curative surgery: a systematic review and meta-analysis | Q38269844 | ||
| Local resection compared with radical resection in the treatment of T1N0M0 rectal adenocarcinoma: a systematic review and meta-analysis | Q38285691 | ||
| Prognostic and Predictive Relevance of Primary Tumor Location in Patients With RAS Wild-Type Metastatic Colorectal Cancer: Retrospective Analyses of the CRYSTAL and FIRE-3 Trials | Q38386724 | ||
| Effect of 3 to 5 years of scheduled CEA and CT follow-up to detect recurrence of colorectal cancer: the FACS randomized clinical trial | Q38437654 | ||
| Neoadjuvant Treatment Strategies for Locally Advanced Rectal Cancer | Q38662196 | ||
| Primary tumor sidedness has an impact on prognosis and treatment outcome in metastatic colorectal cancer: results from two randomized first-line panitumumab studies. | Q38816712 | ||
| Current companion diagnostics in advanced colorectal cancer; getting a bigger and better piece of the pie | Q39172118 | ||
| Total neoadjuvant therapy for rectal cancer: An emerging option | Q39179402 | ||
| Local Excision of Rectal Cancer | Q39304178 | ||
| Immunohistochemistry versus microsatellite instability testing for screening colorectal cancer patients at risk for hereditary nonpolyposis colorectal cancer syndrome. Part I. The utility of immunohistochemistry | Q39514722 | ||
| Peritoneal colorectal carcinomatosis treated with surgery and perioperative intraperitoneal chemotherapy: retrospective analysis of 523 patients from a multicentric French study | Q39928697 | ||
| Tumours with class 3 BRAF mutants are sensitive to the inhibition of activated RAS. | Q40092107 | ||
| Non-V600 BRAF Mutations Define a Clinically Distinct Molecular Subtype of Metastatic Colorectal Cancer. | Q40209192 | ||
| Prognostic and predictive value of primary tumour side in patients with RAS wild-type metastatic colorectal cancer treated with chemotherapy and EGFR directed antibodies in six randomized trials. | Q40243706 | ||
| Predictors of recurrence in patients with T2 and early T3, N0 adenocarcinoma of the rectum treated by surgery alone | Q40292527 | ||
| Cytoreductive surgery and hyperthermic intraperitoneal chemoperfusion versus systemic chemotherapy alone for colorectal peritoneal carcinomatosis. | Q40355978 | ||
| The relevance of primary tumour location in patients with metastatic colorectal cancer: A meta-analysis of first-line clinical trials. | Q40446318 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P433 | issue | 6 | |
| P304 | page(s) | e773-e784 | |
| P577 | publication date | 2019-12-01 | |
| P1433 | published in | Current Oncology | Q3498968 |
| P1476 | title | Report from the 20th annual Western Canadian Gastrointestinal Cancer Consensus Conference; Saskatoon, Saskatchewan; 28-29 September 2018 | |
| P478 | volume | 26 |
Search more.